COMMUNIQUÉS West-GlobeNewswire

Nuvaira annonce la sélection de quatre rapports cliniques pour présentation lors du Congrès international de la SRE

07/09/2017 - 14:00

Le traitement des maladies pulmonaires obstructives chroniques (MPOC) et de l'asthme par dénervation pulmonaire ciblée fera l'objet d'un mini-colloque MILAN, Italie, le 7 septembre 2017 (GLOBE NEWSWIRE) - Nuvaira , un [...]

GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

07/09/2017 - 13:30

PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) ( [...]

Sanofi Alliance Partner Alnylam Gives Update on Fitusiran

07/09/2017 - 13:03

Sanofi Alliance Partner Alnylam Provides Update on Fitusiran Development Program Paris, France - September 7, 2017 - Sanofi alliance partner Alnylam Pharmaceuticals today provided an update on the clinical development [...]

Le partenaire de Sanofi, Alnylam, fait le point sur le programme de développement du fitusiran

07/09/2017 - 13:03

Le partenaire de Sanofi, Alnylam, fait le point sur le programme de développement du fitusiran Paris, France - Le 7 septembre 2017 - Le partenaire de Sanofi , Alnylam Pharmaceuticals, a fait le point aujourd'hui sur le [...]

Medtronic Recognized for Its Sustainability Leadership

07/09/2017 - 13:00

Company Marks a Decade on the North American Dow Jones Sustainability Index (DJSI) DUBLIN - September 7, 2017 - Medtronic plc (NYSE: MDT) was recognized today as one of the world's leading companies for sustainability [...]

Shire to participate at two upcoming investor conferences

07/09/2017 - 13:00

Shire to participate at two upcoming investor conferences Lexington, MA, USA - September 7, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the [...]

Zealand and Orbit Discovery enter into research collaboration

07/09/2017 - 10:07

Company announcement - No. 45 / 2017 Zealand and Orbit Discovery enter into research collaboration Combining Zealand's expertise in discovery and development of peptide therapeutics with Orbit's unique peptide libraries [...]

Helsinn Group supports prIME's Satellite Symposium at ESMO 2017

07/09/2017 - 09:30

Helsinn Group supports prIME's Satellite Symposium at ESMO 2017 World-renowned supportive care experts in oncology explore how to provide the best care for patients by incorporating patient-reported outcomes into the [...]

Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)

07/09/2017 - 08:00

Achieved significant and clinically meaningful additional improvement in peak lung function and faster onset-of-action when added to tiotropium Demonstrated statistical significance across all primary and secondary [...]

Sanofi rated AA by Scope Ratings

07/09/2017 - 07:00

Sanofi rated AA by Scope Ratings Paris, France - September 7, 2017 - Sanofi announced today that the European ratings agency Scope Ratings AG ("Scope") assigned the company a AA long term rating and a S-1+ short-term [...]

Sanofi noté AA par Scope Ratings

07/09/2017 - 07:00

Sanofi noté AA par Scope Ratings Paris, France - Le 7 septembre 2017 - Sanofi annonce aujourd'hui que l'agence européenne de notation de crédit Scope Ratings AG ("Scope") lui a attribué une notation de long-terme AA et [...]

Biocartis Group NV: Biocartis announces H1 2017 results

07/09/2017 - 07:00

PRESS RELEASE: REGULATED INFORMATION Thursday, 7 September 2017, 07:00 CEST BIOCARTIS ANNOUNCES H1 2017 RESULTS Mechelen, Belgium , 7 September 2017 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]

ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON

07/09/2017 - 07:00

GHENT, Belgium, 7 September 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announces that it will participate in the following upcoming investor conferences taking place in London, UK: J.P. Morgan's London [...]

Essilor : Nombre total de droits de vote et d'actions composant le capital social au 31 août 2017

06/09/2017 - 18:00

Nombre total de droits de vote et d'actions composant le capital social au 31 août 2017 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France ( [...]

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2017

06/09/2017 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]

Enzymatica recruits Chief Financial Officer

06/09/2017 - 13:30

Press release Lund, 6 September, 2017 Enzymatica recruits Chief Financial Officer Enzymatica has recruited Therese Filmersson as its new Chief Financial Officer - CFO. Therese joins us from Procurator, one of Sweden's [...]

ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule

06/09/2017 - 13:00

Geneva, Switzerland and Boston, MA - 06 September, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]

Faron Pharmaceuticals Oy: Interim Results for the six months ended 30 June 2017

06/09/2017 - 13:00

Faron Pharmaceuticals Ltd ("Faron" or the "Company") Interim Results for the six months ended 30 June 2017 INTEREST Phase III Traumakine ® trial patient recruitment to complete in Q4 2017 and FDA advice received [...]

Helsinn Group: Announces Upcoming Presentation of Phase III data of NEPA (fosnetupitant/ palonosetron) IV at ESMO 2017

06/09/2017 - 09:30

Helsinn Group Announces Upcoming Presentation of Phase III data of NEPA (fosnetupitant/ palonosetron) IV at ESMO 2017 Preliminary findings demonstrate intravenous NEPA to be safe and well-tolerated, with a similar [...]